Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Second Nasal Drug Delivery Contract

4th Oct 2011 07:00

RNS Number : 4611P
Consort Medical PLC
04 October 2011
 



 

 

News Release

 

4 October 2011

 

 

Consort Medical plc

 

Bespak wins second nasal development contract

Consort Medical plc (LSE: CSRT), today announces that its Bespak Division has been awarded a development contract to deliver a nasal drug delivery device for a major global manufacturer of generic medicines. This is Bespak's second nasal drug delivery device contract.

 

Under the terms of the contract, Bespak will develop its Unidose™ nasal drug delivery device for an undisclosed application. For the first time, Bespak will also fill the device with packaged drug once it goes into production. The device is intended to launch in 2015.

Consort Medical's Bespak Division is a world leader in drug delivery devices. In 2010 it established an Innovations Centre in Cambridge, tasked with diversifying Bespak's core competencies of design for manufacture and high volume manufacture of medical devices into adjacent market areas. This is Bespak's second contract award in the nasal drug device market, which has been driven from the Innovations Centre.

 

Jon Glenn, CEO of Consort Medical, said: "Our Cambridge Innovations Centre is clearly delivering a portfolio of products that leverages our competencies and our technology in adjacent market spaces. This is the second nasal development contract that Bespak has been awarded, and successfully demonstrates our strategy to diversify into new drug delivery markets. In addition, we are moving up the value chain by adding drug filling to our list of competencies."

 

 

For enquiries, please contact:

 

Consort Medical plc

Jonathan Glenn, Chief Executive

Tel: +44 (0) 1442 867920

Toby Woolrych, Group Finance Director

Tel: +44 (0) 1442 867920

Brunswick

Jon Coles/Justine McIlroy/Amie Gramlick

Tel: +44 (0) 20 7404 5959

 

 

Consort Medical plc is a leader in medical devices for inhaled drug delivery, self-injection and anaesthesia. The Group develops drug delivery systems for the pharmaceutical industry and disposable airway management products for critical care settings in hospitals. Consort Medical develops and manufactures metered dose inhaler valves, actuators, compliance aids, dry powder devices autoinjectors, disposable facemasks, breathing circuits and laryngeal tubes. The Group has facilities in King's Lynn, Sheffield, Nelson and Hemel Hempstead in the UK, and Indianapolis, Indiana and Kent, Ohio in the US. Consort Medical is a public company quoted on the full list of the London Stock Exchange (LSE: CSRT).

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTLLFVEIRLVIIL

Related Shares:

CSRT.L
FTSE 100 Latest
Value8,858.10
Change48.36